

Material

Patient 1 - RhD Positive

Patient 2 - RhD Positive

Patient 3 - RhD Negative

Your result

Patient 1

Your Result **Positive** Your score = 0

Overall Results Positive 100% n=(27)

Patient 2

Your Result **Positive** Your score = 0

Overall Results Positive 96.3% n=(26)

Negative 3.7% n=(1)

Patient 3

Your Result **Negative** Your score = 0

Overall Results Negative 96.3% n=(26)

Positive 3.7% n=(1)


Your overall score for this exercise: **RhD** **0**

Definition of Penalty Scores

0-99 Satisfactory
100-150 Unsatisfactory

Your Performance Summary :	Penalty Score this exercise	Cumulative Penalty Score	Cumulative Performance
Non-Return Penalty	0	0	Satisfactory
RhD	0	0	Satisfactory

Your last 3 returns contribute to the cumulative scores



Data analysis

RETURN RATE

26/28 (92.9%) centres returned data by the closing date; however, this report shows 27 results as it includes the UK NEQAS in-house testing.

SAMPLE QUALITY

Satisfactory sample quality was reported for all samples by all centres.

RESULTS

Two centres reported incorrect D types for one patient. The first centre reported Patient 2 (D positive) as D negative and the second centre reported Patient 3 (D negative) as D positive.

Both centres recorded anti-D results which matched the incorrect interpretation; both errors may have been due to sample transposition either during testing or data entry.

Discussion

Testing of EQA samples should, as far as possible, replicate testing for clients. For example, one EQA sample should be taken out and tested at a time, and the same level of checking of transcription steps should apply.

If a D negative client is typed as D positive, they will not receive the anti-D Ig prophylaxis that they require to ensure that they do not make immune anti-D. This exposes future pregnancies to the risk of haemolytic disease of the fetus and newborn (HDFN) due to anti-D.

If a D positive client is typed as D negative, they will receive anti-D Ig unnecessarily. Whilst this poses a lesser risk than inadvertently omitting prophylaxis, anti-D Ig is a blood product and should not be administered where it is not required.